https://scholars.lib.ntu.edu.tw/handle/123456789/495573
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Cornel J.H. | en_US |
dc.contributor.author | Bakris G.L. | en_US |
dc.contributor.author | Stevens S.R. | en_US |
dc.contributor.author | Alvarsson M. | en_US |
dc.contributor.author | Bax W.A. | en_US |
dc.contributor.author | LEE-MING CHUANG | en_US |
dc.contributor.author | Engel S.S. | en_US |
dc.contributor.author | Lopes R.D. | en_US |
dc.contributor.author | McGuire D.K. | en_US |
dc.contributor.author | Riefflin A. | en_US |
dc.contributor.author | Rodbard H.W. | en_US |
dc.contributor.author | Sinay I. | en_US |
dc.contributor.author | Tankova T. | en_US |
dc.contributor.author | Wainstein J. | en_US |
dc.contributor.author | Peterson E.D. | en_US |
dc.contributor.author | Holman R.R. | en_US |
dc.creator | Holman R.R.;Peterson E.D.;Wainstein J.;Tankova T.;Sinay I.;Rodbard H.W.;Riefflin A.;McGuire D.K.;Lopes R.D.;Engel S.S.;LEE-MING CHUANG;Bax W.A.;Alvarsson M.;Stevens S.R.;Bakris G.L.;Cornel J.H. | - |
dc.date.accessioned | 2020-06-01T04:30:41Z | - |
dc.date.available | 2020-06-01T04:30:41Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 0149-5992 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85006117462&doi=10.2337%2fdc16-1415&partnerID=40&md5=6d7feb8ffea34ed8aca2717391b9d499 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/495573 | - |
dc.description.abstract | OBJECTIVE To evaluate chronic kidney disease (CKD) and cardiovascular outcomes in TECOS (Clinical trial reg. no. NCT00790205, clinicaltrials.gov) participants with type 2 diabetes and cardiovascular disease treated with sitagliptin, a dipeptidyl peptidase 4 inhibitor, according to baseline estimated glomerular filtration rate (eGFR). RESEARCH DESIGN AND METHODS We used data from14,671 TECOS participants assigned in a double-blind design to receive sitagliptin or placebo added to existing therapy, while aiming for glycemic equipoise between groups. Cardiovascular and CKD outcomes were evaluated over a median period of 3 years, with participants categorized at baseline into eGFR stages 1, 2, 3a, and 3b (?90, 60-89, 45-59, or 30-44 mL/min/1.73 m2, respectively). RESULTS Participants with eGFR stage 3b were older, were more often female, and had a longer duration of diabetes. Four-point major adverse cardiovascular event rates increasedwith lower baseline eGFR (3.52, 3.55, 5.74, and 7.34 events/100 patientyears for stages 1-3b, respectively). Corresponding adjusted hazard ratios for stages 2, 3a, and 3b versus stage 1 were 0.93 (95% CI 0.82-1.06), 1.28 (1.10-1.49), and 1.39 (1.13-1.72), respectively. Sitagliptin therapy was not associated with cardiovascular outcomes for any eGFR stage (interaction P values were all >0.44). Kidney function declined at the same rate in both treatment groups, with a marginally lower but constant eGFR difference (21.3 mL/min/1.73 m2) in those participants who were assigned to sitagliptin. Treatment differences in these eGFR values remained after adjustment for region, baseline eGFR, baseline HbA1c, time of assessment, and within-study HbA1c levels. CONCLUSIONS Impaired kidney function is associated with worse cardiovascular outcomes. Sitagliptin has no clinically significant impact on cardiovascular or CKD outcomes, irrespective of baseline eGFR. | - |
dc.publisher | American Diabetes Association Inc. | - |
dc.relation.ispartof | Diabetes Care | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | hemoglobin A1c; placebo; sitagliptin; antidiabetic agent; dipeptidyl peptidase IV inhibitor; sitagliptin; adult; age; albuminuria; cardiovascular function; chronic kidney failure; Conference Paper; controlled study; creatinine clearance; disease classification; disease duration; double blind procedure; drug effect; female; gender; glomerulus filtration rate; glycemic control; hemoglobin blood level; human; kidney function; major clinical study; male; non insulin dependent diabetes mellitus; outcome assessment; randomized controlled trial; aged; Cardiovascular Diseases; clinical trial; complication; Diabetes Mellitus, Type 2; drug effects; kidney; middle aged; multicenter study; pathophysiology; Renal Insufficiency, Chronic; treatment outcome; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Treatment Outcome | - |
dc.title | Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: Outcomes from TECOS | en_US |
dc.type | conference paper | en |
dc.identifier.doi | 10.2337/dc16-1415 | - |
dc.identifier.pmid | 27742728 | - |
dc.identifier.scopus | 2-s2.0-85006117462 | - |
dc.relation.pages | 2304-2310 | - |
dc.relation.journalvolume | 39 | - |
dc.relation.journalissue | 12 | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_5794 | - |
item.openairetype | conference paper | - |
item.grantfulltext | none | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.orcid | 0000-0003-0978-2662 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。